[
  {
    "ts": null,
    "headline": "Tracking The ~$14B Lone Pine Capital Portfolio - Q2 2025 Update",
    "summary": "Get the latest on Lone Pine Capital's Q2 2025 portfolio: top stock picks, new investments, major exits, and strategic moves.",
    "url": "https://finnhub.io/api/news?id=bd162d0a96d9e4d5d5a33f24a441e963314dabe3f7877563f2f631cea6755c3f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759174911,
      "headline": "Tracking The ~$14B Lone Pine Capital Portfolio - Q2 2025 Update",
      "id": 136919367,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1143979227/image_1143979227.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get the latest on Lone Pine Capital's Q2 2025 portfolio: top stock picks, new investments, major exits, and strategic moves.",
      "url": "https://finnhub.io/api/news?id=bd162d0a96d9e4d5d5a33f24a441e963314dabe3f7877563f2f631cea6755c3f"
    }
  },
  {
    "ts": null,
    "headline": "Alexandria & Lilly Unite at San Diego's One Alexandria Square",
    "summary": "ARE and Lilly open Lilly Gateway Labs in San Diego, expanding biotech innovation with advanced labs and collaborative space.",
    "url": "https://finnhub.io/api/news?id=6d81e9090436c13deaa2fbfedca802ae50a5d4f73af7fb7781e5b85013f2cb70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759169700,
      "headline": "Alexandria & Lilly Unite at San Diego's One Alexandria Square",
      "id": 136923771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ARE and Lilly open Lilly Gateway Labs in San Diego, expanding biotech innovation with advanced labs and collaborative space.",
      "url": "https://finnhub.io/api/news?id=6d81e9090436c13deaa2fbfedca802ae50a5d4f73af7fb7781e5b85013f2cb70"
    }
  },
  {
    "ts": null,
    "headline": "Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?",
    "summary": "As the battle for dominance heats up in the weight loss market, which stock is a better investment now?",
    "url": "https://finnhub.io/api/news?id=519ce986b09d585e829d71f6681360b42cf39b3d235d85fe2645863775a4165e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759163637,
      "headline": "Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?",
      "id": 136923773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the battle for dominance heats up in the weight loss market, which stock is a better investment now?",
      "url": "https://finnhub.io/api/news?id=519ce986b09d585e829d71f6681360b42cf39b3d235d85fe2645863775a4165e"
    }
  },
  {
    "ts": null,
    "headline": "How Eli Lilly (LLY) Balances Dividend Payouts With Long-Term Innovation",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 11 Best Value Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) , which has been around since the late 1800s, has built a strong track record in developing and selling drugs for diabetes, cancer, and immunology, including treatments for rheumatoid arthritis and other conditions. Three […]",
    "url": "https://finnhub.io/api/news?id=b2e315cdd6158d8c9560d2be8c8eb7e3dc7624249f4f7e49558f90eda19a932f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759163602,
      "headline": "How Eli Lilly (LLY) Balances Dividend Payouts With Long-Term Innovation",
      "id": 136923775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 11 Best Value Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) , which has been around since the late 1800s, has built a strong track record in developing and selling drugs for diabetes, cancer, and immunology, including treatments for rheumatoid arthritis and other conditions. Three […]",
      "url": "https://finnhub.io/api/news?id=b2e315cdd6158d8c9560d2be8c8eb7e3dc7624249f4f7e49558f90eda19a932f"
    }
  },
  {
    "ts": null,
    "headline": "Trials to watch: Three major catalysts in Alzheimer’s disease",
    "summary": "While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms of action.",
    "url": "https://finnhub.io/api/news?id=2c47ac85e7346223b1ec78c54d1abfde6d411e2870e3bf003a77e55cc584bc53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759155799,
      "headline": "Trials to watch: Three major catalysts in Alzheimer’s disease",
      "id": 136915665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms of action.",
      "url": "https://finnhub.io/api/news?id=2c47ac85e7346223b1ec78c54d1abfde6d411e2870e3bf003a77e55cc584bc53"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Is Downgraded. There’s a ‘Tough Path Ahead.’",
    "summary": "U.S. prescriptions for Novo's Ozempic and Wegovy drugs are stagnating, Morgan Stanley analysts said.",
    "url": "https://finnhub.io/api/news?id=8f5aea8231a5b4ff7bbfb65eb03704784018b1b09c8ccd3e8bb08f4453d4c055",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759155180,
      "headline": "Novo Nordisk Stock Is Downgraded. There’s a ‘Tough Path Ahead.’",
      "id": 136915666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. prescriptions for Novo's Ozempic and Wegovy drugs are stagnating, Morgan Stanley analysts said.",
      "url": "https://finnhub.io/api/news?id=8f5aea8231a5b4ff7bbfb65eb03704784018b1b09c8ccd3e8bb08f4453d4c055"
    }
  },
  {
    "ts": null,
    "headline": "Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?",
    "summary": "Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.",
    "url": "https://finnhub.io/api/news?id=17d7a30dbbde8aba7d82cbc0e871b944094ca71e7c322738e63bfd69ec3ce668",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759154640,
      "headline": "Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?",
      "id": 136915667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.",
      "url": "https://finnhub.io/api/news?id=17d7a30dbbde8aba7d82cbc0e871b944094ca71e7c322738e63bfd69ec3ce668"
    }
  },
  {
    "ts": null,
    "headline": "dHealth Intelligence Launches Revolutionary AI Agent That Transforms Personal Healthcare Management",
    "summary": "ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2025 / Healthcare AI startupdHealth Intelligencejust unveiled an AI agent that consolidates fragmented medical data & provides advice based on it, while protecting patient privacy. Available now ...",
    "url": "https://finnhub.io/api/news?id=b5bad2ed178358e6adb46d788077bd8819d7f357b6ed58d617bc37b3644c4ad3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759153800,
      "headline": "dHealth Intelligence Launches Revolutionary AI Agent That Transforms Personal Healthcare Management",
      "id": 136915668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2025 / Healthcare AI startupdHealth Intelligencejust unveiled an AI agent that consolidates fragmented medical data & provides advice based on it, while protecting patient privacy. Available now ...",
      "url": "https://finnhub.io/api/news?id=b5bad2ed178358e6adb46d788077bd8819d7f357b6ed58d617bc37b3644c4ad3"
    }
  },
  {
    "ts": null,
    "headline": "Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States",
    "summary": "SAN DIEGO, September 29, 2025--t:slim X2 insulin pump with Control-IQ+ technology now cleared for use with Lyumjev ultra-rapid acting insulin in the U.S.",
    "url": "https://finnhub.io/api/news?id=eb4152cecc6b74fed345fbac20617590b7599d8e6c63501a033ded0c4ff6d7d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759149000,
      "headline": "Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States",
      "id": 136915669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN DIEGO, September 29, 2025--t:slim X2 insulin pump with Control-IQ+ technology now cleared for use with Lyumjev ultra-rapid acting insulin in the U.S.",
      "url": "https://finnhub.io/api/news?id=eb4152cecc6b74fed345fbac20617590b7599d8e6c63501a033ded0c4ff6d7d0"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer",
    "summary": "PALO ALTO, Calif., September 29, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from Eli Lilly and Company’s Inluriyo (imlunestrant). Guardant360 CDx was approved in conjunction with Inluriyo for the treatment of adults with estrogen receptor-positive (ER+), hum",
    "url": "https://finnhub.io/api/news?id=c1374ca94b392c88a79db32b8c6b7a906cbc086ecc1ea566d8e96a129859f472",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759147500,
      "headline": "FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer",
      "id": 136914177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PALO ALTO, Calif., September 29, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from Eli Lilly and Company’s Inluriyo (imlunestrant). Guardant360 CDx was approved in conjunction with Inluriyo for the treatment of adults with estrogen receptor-positive (ER+), hum",
      "url": "https://finnhub.io/api/news?id=c1374ca94b392c88a79db32b8c6b7a906cbc086ecc1ea566d8e96a129859f472"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth",
    "summary": "Eli Lillyâs valuation has compressed significantly from last yearâs highs, despite improving fundamentals. See why I rate LLY stock a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=4334827bbd08026555b57560a625d3c32f8cf6606ec069078906ba88ee7dd9fb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759141587,
      "headline": "Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth",
      "id": 136915125,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503336/image_521503336.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lillyâs valuation has compressed significantly from last yearâs highs, despite improving fundamentals. See why I rate LLY stock a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=4334827bbd08026555b57560a625d3c32f8cf6606ec069078906ba88ee7dd9fb"
    }
  },
  {
    "ts": null,
    "headline": "As obesity M&A heats up, pharmas could get ‘blinded by opportunity’",
    "summary": "With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.",
    "url": "https://finnhub.io/api/news?id=a1d8f8a7efc5de2300d4204e505fd5f857e8433023da8bf00e1180be42da0f62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759133957,
      "headline": "As obesity M&A heats up, pharmas could get ‘blinded by opportunity’",
      "id": 136914591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.",
      "url": "https://finnhub.io/api/news?id=a1d8f8a7efc5de2300d4204e505fd5f857e8433023da8bf00e1180be42da0f62"
    }
  },
  {
    "ts": null,
    "headline": "Heard on the Street Friday Recap: Another Dose of Tariffs",
    "summary": "President Trump unveiled 100% tariffs on pharmaceuticals. The levies only apply to patented or branded drugs from companies that aren't building plants in the U.S. Shares of drugmakers such as Eli Lilly, AstraZeneca and GSK rose slightly.",
    "url": "https://finnhub.io/api/news?id=27e4c1e6c7be05ec6963d6785e1312b9e30830decc80abb89f54e72688ecf1a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759128445,
      "headline": "Heard on the Street Friday Recap: Another Dose of Tariffs",
      "id": 136913586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump unveiled 100% tariffs on pharmaceuticals. The levies only apply to patented or branded drugs from companies that aren't building plants in the U.S. Shares of drugmakers such as Eli Lilly, AstraZeneca and GSK rose slightly.",
      "url": "https://finnhub.io/api/news?id=27e4c1e6c7be05ec6963d6785e1312b9e30830decc80abb89f54e72688ecf1a4"
    }
  },
  {
    "ts": null,
    "headline": "Novo, Lilly Weight-Loss Drugs May Help Alzheimer’s Patients. What It Means for the Stocks.",
    "summary": "Novo Nordisk stock has fallen more than 60% since its peak in mid-2024 and the weight-loss drug maker badly needs a boost.  It could come soon if Alzheimer’s disease proves to be the next frontier for so-called GLP-1 drugs.  The benefits of  Novo Nordisk  and  Eli Lilly’s  GLP-1 drugs have swelled beyond diabetes and obesity to include cardiovascular and liver disease since Ozempic hit the market in 2017.",
    "url": "https://finnhub.io/api/news?id=40c0543d29ccc9b8bbde72251ad2b5cbec982af53c8d2442d583764879260538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759125600,
      "headline": "Novo, Lilly Weight-Loss Drugs May Help Alzheimer’s Patients. What It Means for the Stocks.",
      "id": 136913587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock has fallen more than 60% since its peak in mid-2024 and the weight-loss drug maker badly needs a boost.  It could come soon if Alzheimer’s disease proves to be the next frontier for so-called GLP-1 drugs.  The benefits of  Novo Nordisk  and  Eli Lilly’s  GLP-1 drugs have swelled beyond diabetes and obesity to include cardiovascular and liver disease since Ozempic hit the market in 2017.",
      "url": "https://finnhub.io/api/news?id=40c0543d29ccc9b8bbde72251ad2b5cbec982af53c8d2442d583764879260538"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains a Buy on Pfizer Inc (PFE), Keeps the PT",
    "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $30. ​The analyst pointed to the company’s recent acquisition of Metsera. He noted that the deal allows […]",
    "url": "https://finnhub.io/api/news?id=d0dc747e97289ec5b10e96de8579e89aff04515dcd91534394b476581008f7c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759124375,
      "headline": "BMO Capital Maintains a Buy on Pfizer Inc (PFE), Keeps the PT",
      "id": 136913588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $30. ​The analyst pointed to the company’s recent acquisition of Metsera. He noted that the deal allows […]",
      "url": "https://finnhub.io/api/news?id=d0dc747e97289ec5b10e96de8579e89aff04515dcd91534394b476581008f7c8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Plans $6.5B Investment to Bolster Pipeline Production",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long-term growth stocks to buy and hold forever. On September 23, the company announced plans to invest $6.5 billion in the construction of a manufacturing facility in Texas. The construction is part of the company’s push to boost pipeline production of the so-called small molecule […]",
    "url": "https://finnhub.io/api/news?id=4ecea264db8141b1b27bc043a31e5dbbe75b06d25fad5c19e30ab0161bcc96c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759121803,
      "headline": "Eli Lilly and Company (LLY) Plans $6.5B Investment to Bolster Pipeline Production",
      "id": 136913589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long-term growth stocks to buy and hold forever. On September 23, the company announced plans to invest $6.5 billion in the construction of a manufacturing facility in Texas. The construction is part of the company’s push to boost pipeline production of the so-called small molecule […]",
      "url": "https://finnhub.io/api/news?id=4ecea264db8141b1b27bc043a31e5dbbe75b06d25fad5c19e30ab0161bcc96c4"
    }
  }
]